Publication: CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
28
Issued Date
2013-08-28
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-84882748728
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.6, No.1 (2013), 85-91
Suggested Citation
Chonlaphat Sukasem, Ramaimon Tunthong, Montri Chamnanphon, Siwalee Santon, Thawinee Jantararoungtong, Napatrupron Koomdee, Santirhat Prommas, Apichaya Puangpetch, Prin Vathesatogkit CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharmacogenomics and Personalized Medicine. Vol.6, No.1 (2013), 85-91. doi:10.2147/PGPM.S42332 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/31236
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
Other Contributor(s)
Abstract
Genetic variation in the cytochrome P450 2C19 (CYP2C19) gene has been documented gradually as the determinant conversion and variability in the antiplatelet effect of clopidogrel. The aims of this study were to determine the prevalence of clinically relevant allele variants (CYP2C19*2, CYP2C19*3, and CYP2C19*17) in a Thai study population, and finally determine whether the allele distributes and predicts metabolic phenotypes in clopidogrel treated patients. A total of 1,051 Thai patients participated in this study. Genotypes for CYP2C19 polymorphisms were detected by the microarray-based technique. Furthermore, results of genotyping and platelet aggregation in 96 cardiovascular disease patients on 75 mg clopidogrel maintenance daily dose therapy also were analyzed. Among 1,051 samples, the allele frequencies of CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *1/*17 were found in 428 (40.72%), 369 (35.10%), 72 (6.85%), 77 (7.32%), 59 (5.61%), and 45 (4.30%) of the patients, respectively. Homozygous CYP2C19 *3/*3 was found in one patient (0.10%). Therefore, 40.72% of the patients were predicted as extensive metabolizers, 41.95% as intermediate metabolizers, 13.03% as poor metabolizers, and 4.30% as ultra-rapid metabolizers. Among 96 patients, the frequency of poor metabolizers was significantly higher in the clopidogrel non-responder group than in the responder group (36.0% and 15.5%, respectively, P = 0.03). CYP2C19*1/*17 was observed in responders (n = 2; 2.8%). As a result, CYP2C19 variants were associated with clopidogrel non-responders. However, there is a need for further elucidation of the clinical importance and use of this finding to make firm and cost-effective recommendations for drug treatment in the future. © 2013 Sukasem et al, publisher and licensee Dove Medical Press Ltd.